MedPath

Clareon PanOptix Pro vs. Clareon PanOptix - Study A

Not Applicable
Completed
Conditions
Presbyopia
Aphakia
Interventions
Device: CPO Pro IOL
Device: CPO IOL
Procedure: Cataract surgery
Registration Number
NCT06400745
Lead Sponsor
Alcon Research
Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.

Detailed Description

Subjects will attend 9 scheduled study visits for a total individual duration of participation of approximately 7 months. The primary endpoint will be assessed at the Month 2 follow-up visit. Both eyes of a subject must qualify for enrollment into this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
161
Inclusion Criteria
  • Understand and sign an ethics committee-approved informed consent form;
  • Willing and able to attend all scheduled study visits as required by the protocol;
  • Planned cataract surgery (both eyes);
  • Preoperative corneal astigmatism less that 1.00 diopter in each eye.
  • Other protocol-defined inclusion criteria may apply.

Key

Exclusion Criteria
  • Women of childbearing potential if currently pregnant, intend to become pregnant during the study, or are breastfeeding;
  • Ocular conditions as specified in the protocol;
  • Subjects who desire monovision correction.
  • Other protocol-defined exclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CPO Pro IOLCPO Pro IOLCPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
CPO Pro IOLCPO IOLCPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
CPO IOLCPO Pro IOLCPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
CPO Pro IOLCataract surgeryCPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
CPO IOLCPO IOLCPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
CPO IOLCataract surgeryCPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
Primary Outcome Measures
NameTimeMethod
Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA)Month 2 postoperative

Visual Acuity (VA) will be assessed for each eye individually using Early Treatment Diabetic Retinopathy Study (ETDRS) reading charts at a distance of 4 meters from the subject under photopic (well-lit) conditions with correction in place. BCDVA will be measured in logarithm Minimum Angle of Resolution (logMAR). LogMAR values typically range from -0.3 (20/10 vision on the Snellen chart) to 1 (20/200 vision), with lower scores indicating better vision.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (8)

Wolstan & Goldberg Eye Associates

🇺🇸

Torrance, California, United States

Grosinger, Spigelman & Grey Eye Surgeons, P.C.

🇺🇸

Bloomfield Hills, Michigan, United States

Moyes Eye Center

🇺🇸

Kansas City, Missouri, United States

Cincinnati Eye Institute

🇺🇸

Cincinnati, Ohio, United States

Carolina Eyecare Physicians, LLC

🇺🇸

Mount Pleasant, South Carolina, United States

Vision for Life

🇺🇸

Nashville, Tennessee, United States

Houston Eye Associates

🇺🇸

Houston, Texas, United States

The Eye Institute of Utah

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath